Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Effect of olezarsen on lipoprotein-associated ApoC-III levels in patients with familial chylomicronemia syndrome

21 Jul 2025

Abstract excerpt

BACKGROUND: Apolipoprotein C-III (apoC-III) is transported on chylomicrons, very-low-density lipoprotein (VLDL), low-density lipoprotein (LDL), high-density lipoprotein (HDL) and lipoprotein(a) [Lp(a)]. Olezarsen, a hepatic-targeted antisense oligonucleotide targeting APOC3 mRNA, lowers apoC-III and triglycerides and reduces pancreatitis events. This study evaluated the reduction of apoC-III in specific...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Caveolin-1 and cellular processes
Share to Diabetes, Cardiovascular Risks, and Lipoproteins
Share to Lipid metabolism and disorders

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Source

Identifiers

PMID: 40706406
DOI: 10.1016/j.atherosclerosis.2025.120462

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Effect of olezarsen on lipoprotein-associated ApoC-III levels in patients with familial chylomicronemia syndromePMID 40706406Read ↗

Novel Therapeutics for Familial Chylomicronemia SyndromeSemantic proximity Read ↗

Clinical identification of familial chylomicronemia syndrome and novel therapeutic options.Semantic proximity Read ↗

Targeting APOC3 in the familial chylomicronemia syndrome.Semantic proximity Read ↗

Drug target Mendelian randomization supports apolipoprotein C3-lowering for lipoprotein-lipid levels reductions and cardiovascular diseases prevention.Semantic proximity Read ↗

Familial chylomicronemia syndrome and treatments to target hepatic APOC3 mRNASemantic proximity Read ↗

Differential effects of volanesorsen on apoC-III, triglycerides, and pancreatitis in familial chylomicronemia syndrome diagnosed by genetic or nongenetic criteriaSemantic proximity Read ↗

Evinacumab in severe hypertriglyceridemia with or without lipoprotein lipase pathway mutations: a phase 2 randomized trial.Semantic proximity Read ↗

ApoC-III inhibits clearance of triglyceride-rich lipoproteins through LDL family receptors.Semantic proximity Read ↗

Postprandial metabolism of apolipoproteins B48, B100, C-III, and E in humans with APOC3 loss-of-function mutations.Semantic proximity Read ↗

Clinical Intervention to Reduce Dietary Sugar Does Not Affect Liver Fat in Latino Youth, Regardless of PNPLA3 Genotype: A Randomized Controlled Trial.Semantic proximity Read ↗

Apolipoprotein C-III inhibition with volanesorsen in patients with hypertriglyceridemia (COMPASS): A randomized, double-blind, placebo-controlled trialSemantic proximity Read ↗

Post-prandial Analysis of Fluctuations in the Platelet Count and Platelet Activity in Patients with the Familial Chylomicronemia SyndromeSemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.